PRGO Perrigo Corp: Enterprise Value to EBITDA Ratio
Perrigo Company plc (PRGO) faces pressure from price wars and regulatory scrutiny, creating risks for stability. However, its status as a leading private label supplier allows the company to displace expensive brands through scale. The modernization of production facilities ensures continuous output. This chart on GURU.Markets contains the company's EV/EBITDA value, where 8.73 expresses the current value of the metric today.
Comprehensive metric breakdowns and analytics for perrigo.com (PRGO)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
PRGO - Final Profit|Projected Future Earnings Perrigo Company plc|PRGO - Business Payback Period|Forward P/E Multiple Perrigo Company plc|PRGO - Price to Net Income Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Perrigo Corp|PRGO - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Perrigo|PRGO - Earnings per share for the trailing year|Quarterly EPS earnings growth perrigo.com|PRGO - Net earnings per share growth this year|Net earnings per share growth forecast for next year Perrigo Company plc
Fundamental valuation:Perrigo Company PRGO
Professional capital evaluates Perrigo Company plc (PRGO) through the lens of its ability to generate cash flow to service obligations during the restructuring period. By analyzing the historical EV/EBITDA multiple, the investor compares the total enterprise value with operating profit before taxes and amortization, which allows for an assessment of debt management efficiency and confirms the asset's resilience during brand portfolio optimization.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|ALVO (Alvotech Corp) - EV/EBITDA Multiple|Company Value to EBITDA Liquidia Inc. LQDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MannKind MNKD|AMPH (Amphastar Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Pacira - EV/EBITDA Multiple|Company Value to EBITDA ARS Corp|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|aquestive.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scPharmaceuticals, Inc.|TECX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNXP|Total Company Value to Operating Income Before Depreciation Ratio sxtchina.com|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|Enterprise Value to EBITDA Multiple bioharvest.com|EXOZ - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Oramed Pharmaceuticals|ENTX (enterabio.com) - Enterprise Value to EBITDA Ratio|MindWalk Therapeutics - Business Value to Operating Income Before Depreciation|ABVC (ABVC BioPharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cumberlandpharma.com (CPIX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Quantum BioPharma (QNTM)|FGEN - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|RANI - Enterprise Value to EBITDA Ratio|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RLYB|LEXX: EV/EBITDA Multiple|Pulmatrix Inc (PULM) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|Enterprise Value to Operating Income Before Depreciation APM (Aptorum)|Enterprise Value to EBITDA Ratio LYRA (Lyra Therapeutics, Inc.)|IBO - Company Value to EBITDA|TNF Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CYTO|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OPTN (optinose.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Procaps Group (PROC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI: Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Business Value to Operating Income Before Depreciation TFFP
